Abstract
Summary
Viral Vector Manufacturing for Gene Therapy refers to the specialized process of producing viral vectors, which are engineered viruses used to deliver therapeutic genetic material into patients' cells. This process involves several stages, including design, production, purification, and quality control, to ensure that the viral vectors are safe, effective, and compliant with regulatory standards.
Viral vector manufacturing is crucial for the development and delivery of gene therapies, which aim to treat genetic disorders, cancers, and other diseases by introducing, removing, or altering genetic material within a patient’s cells. The manufacturing process ensures that these therapies are safe, effective, and ready for clinical use.
The global Viral Vector Manufacturing for Gene Therapy market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of %during the forecast period.
The US & Canada market for Viral Vector Manufacturing for Gene Therapy is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The China market for Viral Vector Manufacturing for Gene Therapy is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The Europe market for Viral Vector Manufacturing for Gene Therapy is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key manufacturers of Viral Vector Manufacturing for Gene Therapy include Thermo Fisher Scientific, Lonza, Catalent, Charles River, Merck, SK pharmteco, Oxford Biomedica, AGC Biologics（MolMed）, Gene Universal, Polyplus (Sartorius), etc. In 2023, the global top five players had a share approximately % in terms of revenue.
Report Includes
This report presents an overview of global market for Viral Vector Manufacturing for Gene Therapy market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Viral Vector Manufacturing for Gene Therapy, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Viral Vector Manufacturing for Gene Therapy, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Viral Vector Manufacturing for Gene Therapy revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Viral Vector Manufacturing for Gene Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Viral Vector Manufacturing for Gene Therapy revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Thermo Fisher Scientific, Lonza, Catalent, Charles River, Merck, SK pharmteco, Oxford Biomedica, AGC Biologics（MolMed）, Gene Universal, Polyplus (Sartorius), etc.
Market Segmentation
By Company
Thermo Fisher Scientific
Lonza
Catalent
Charles River
Merck
SK pharmteco
Oxford Biomedica
AGC Biologics（MolMed）
Gene Universal
Polyplus (Sartorius)
CCRM
FUJIFILM Diosynth Biotechnologies
Biovian
Miltenyi Bioindustry
Aldevron
Takara Bio
Yposkesi
Genezen
Exthera
Flash Therapeutics
VIVEBiotech
FinVector
Eurogentec
VGXI
GenScript ProBio
EurekaBio
Obio Technology
GeneSail Biotech
VectorBuilder
WuXi ATU
Ubrigene
Porton Biologics
Pharmaron
PackGene Biotechnology
Hillgene
Asymchem
Segment by Type
AAV
Lentivirus
Adenovirus
HSV
Others
Segment by Application
Vaccine Development
Gene Therapy
Academic Scientific Research Institution
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of South America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Viral Vector Manufacturing for Gene Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Viral Vector Manufacturing for Gene Therapy companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Viral Vector Manufacturing for Gene Therapy revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Viral vector manufacturing is crucial for the development and delivery of gene therapies, which aim to treat genetic disorders, cancers, and other diseases by introducing, removing, or altering genetic material within a patient’s cells. The manufacturing process ensures that these therapies are safe, effective, and ready for clinical use.
The global Viral Vector Manufacturing for Gene Therapy market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of %during the forecast period.
The US & Canada market for Viral Vector Manufacturing for Gene Therapy is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The China market for Viral Vector Manufacturing for Gene Therapy is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The Europe market for Viral Vector Manufacturing for Gene Therapy is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key manufacturers of Viral Vector Manufacturing for Gene Therapy include Thermo Fisher Scientific, Lonza, Catalent, Charles River, Merck, SK pharmteco, Oxford Biomedica, AGC Biologics（MolMed）, Gene Universal, Polyplus (Sartorius), etc. In 2023, the global top five players had a share approximately % in terms of revenue.
Report Includes
This report presents an overview of global market for Viral Vector Manufacturing for Gene Therapy market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Viral Vector Manufacturing for Gene Therapy, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Viral Vector Manufacturing for Gene Therapy, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Viral Vector Manufacturing for Gene Therapy revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Viral Vector Manufacturing for Gene Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Viral Vector Manufacturing for Gene Therapy revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Thermo Fisher Scientific, Lonza, Catalent, Charles River, Merck, SK pharmteco, Oxford Biomedica, AGC Biologics（MolMed）, Gene Universal, Polyplus (Sartorius), etc.
Market Segmentation
By Company
Thermo Fisher Scientific
Lonza
Catalent
Charles River
Merck
SK pharmteco
Oxford Biomedica
AGC Biologics（MolMed）
Gene Universal
Polyplus (Sartorius)
CCRM
FUJIFILM Diosynth Biotechnologies
Biovian
Miltenyi Bioindustry
Aldevron
Takara Bio
Yposkesi
Genezen
Exthera
Flash Therapeutics
VIVEBiotech
FinVector
Eurogentec
VGXI
GenScript ProBio
EurekaBio
Obio Technology
GeneSail Biotech
VectorBuilder
WuXi ATU
Ubrigene
Porton Biologics
Pharmaron
PackGene Biotechnology
Hillgene
Asymchem
Segment by Type
AAV
Lentivirus
Adenovirus
HSV
Others
Segment by Application
Vaccine Development
Gene Therapy
Academic Scientific Research Institution
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of South America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Viral Vector Manufacturing for Gene Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Viral Vector Manufacturing for Gene Therapy companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Viral Vector Manufacturing for Gene Therapy revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Viral Vector Manufacturing for Gene Therapy Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 AAV
1.2.3 Lentivirus
1.2.4 Adenovirus
1.2.5 HSV
1.2.6 Others
1.3 Market by Application
1.3.1 Global Viral Vector Manufacturing for Gene Therapy Market Share by Application: 2019 VS 2023 VS 2030
1.3.2 Vaccine Development
1.3.3 Gene Therapy
1.3.4 Academic Scientific Research Institution
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Viral Vector Manufacturing for Gene Therapy Market Perspective (2019-2030)
2.2 Global Viral Vector Manufacturing for Gene Therapy Growth Trends by Region
2.2.1 Global Viral Vector Manufacturing for Gene Therapy Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Viral Vector Manufacturing for Gene Therapy Historic Market Size by Region (2019-2024)
2.2.3 Viral Vector Manufacturing for Gene Therapy Forecasted Market Size by Region (2025-2030)
2.3 Viral Vector Manufacturing for Gene Therapy Market Dynamics
2.3.1 Viral Vector Manufacturing for Gene Therapy Industry Trends
2.3.2 Viral Vector Manufacturing for Gene Therapy Market Drivers
2.3.3 Viral Vector Manufacturing for Gene Therapy Market Challenges
2.3.4 Viral Vector Manufacturing for Gene Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Viral Vector Manufacturing for Gene Therapy by Players
3.1.1 Global Viral Vector Manufacturing for Gene Therapy Revenue by Players (2019-2024)
3.1.2 Global Viral Vector Manufacturing for Gene Therapy Revenue Market Share by Players (2019-2024)
3.2 Global Viral Vector Manufacturing for Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Viral Vector Manufacturing for Gene Therapy, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Viral Vector Manufacturing for Gene Therapy Market Concentration Ratio
3.4.1 Global Viral Vector Manufacturing for Gene Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Viral Vector Manufacturing for Gene Therapy Revenue in 2023
3.5 Global Key Players of Viral Vector Manufacturing for Gene Therapy Head office and Area Served
3.6 Global Key Players of Viral Vector Manufacturing for Gene Therapy, Product and Application
3.7 Global Key Players of Viral Vector Manufacturing for Gene Therapy, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Viral Vector Manufacturing for Gene Therapy Breakdown Data by Type
4.1 Global Viral Vector Manufacturing for Gene Therapy Historic Market Size by Type (2019-2024)
4.2 Global Viral Vector Manufacturing for Gene Therapy Forecasted Market Size by Type (2025-2030)
5 Viral Vector Manufacturing for Gene Therapy Breakdown Data by Application
5.1 Global Viral Vector Manufacturing for Gene Therapy Historic Market Size by Application (2019-2024)
5.2 Global Viral Vector Manufacturing for Gene Therapy Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Viral Vector Manufacturing for Gene Therapy Market Size (2019-2030)
6.2 North America Viral Vector Manufacturing for Gene Therapy Market Size by Type
6.2.1 North America Viral Vector Manufacturing for Gene Therapy Market Size by Type (2019-2024)
6.2.2 North America Viral Vector Manufacturing for Gene Therapy Market Size by Type (2025-2030)
6.2.3 North America Viral Vector Manufacturing for Gene Therapy Market Share by Type (2019-2030)
6.3 North America Viral Vector Manufacturing for Gene Therapy Market Size by Application
6.3.1 North America Viral Vector Manufacturing for Gene Therapy Market Size by Application (2019-2024)
6.3.2 North America Viral Vector Manufacturing for Gene Therapy Market Size by Application (2025-2030)
6.3.3 North America Viral Vector Manufacturing for Gene Therapy Market Share by Application (2019-2030)
6.4 North America Viral Vector Manufacturing for Gene Therapy Market Size by Country
6.4.1 North America Viral Vector Manufacturing for Gene Therapy Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Viral Vector Manufacturing for Gene Therapy Market Size by Country (2019-2024)
6.4.3 North America Viral Vector Manufacturing for Gene Therapy Market Share by Country (2025-2030)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Viral Vector Manufacturing for Gene Therapy Market Size (2019-2030)
7.2 Europe Viral Vector Manufacturing for Gene Therapy Market Size by Type
7.2.1 Europe Viral Vector Manufacturing for Gene Therapy Market Size by Type (2019-2024)
7.2.2 Europe Viral Vector Manufacturing for Gene Therapy Market Size by Type (2025-2030)
7.2.3 Europe Viral Vector Manufacturing for Gene Therapy Market Share by Type (2019-2030)
7.3 Europe Viral Vector Manufacturing for Gene Therapy Market Size by Application
7.3.1 Europe Viral Vector Manufacturing for Gene Therapy Market Size by Application (2019-2024)
7.3.2 Europe Viral Vector Manufacturing for Gene Therapy Market Size by Application (2025-2030)
7.3.3 Europe Viral Vector Manufacturing for Gene Therapy Market Share by Application (2019-2030)
7.4 Europe Viral Vector Manufacturing for Gene Therapy Market Size by Country
7.4.1 Europe Viral Vector Manufacturing for Gene Therapy Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Viral Vector Manufacturing for Gene Therapy Market Size by Country (2019-2024)
7.4.3 Europe Viral Vector Manufacturing for Gene Therapy Market Size by Country (2025-2030)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
7.4.9 Nordic Countries
8 China
8.1 China Viral Vector Manufacturing for Gene Therapy Market Size (2019-2030)
8.2 China Viral Vector Manufacturing for Gene Therapy Market Size by Type
8.2.1 China Viral Vector Manufacturing for Gene Therapy Market Size by Type (2019-2024)
8.2.2 China Viral Vector Manufacturing for Gene Therapy Market Size by Type (2025-2030)
8.2.3 China Viral Vector Manufacturing for Gene Therapy Market Share by Type (2019-2030)
8.3 China Viral Vector Manufacturing for Gene Therapy Market Size by Application
8.3.1 China Viral Vector Manufacturing for Gene Therapy Market Size by Application (2019-2024)
8.3.2 China Viral Vector Manufacturing for Gene Therapy Market Size by Application (2025-2030)
8.3.3 China Viral Vector Manufacturing for Gene Therapy Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Viral Vector Manufacturing for Gene Therapy Market Size (2019-2030)
9.2 Asia Viral Vector Manufacturing for Gene Therapy Market Size by Type
9.2.1 Asia Viral Vector Manufacturing for Gene Therapy Market Size by Type (2019-2024)
9.2.2 Asia Viral Vector Manufacturing for Gene Therapy Market Size by Type (2025-2030)
9.2.3 Asia Viral Vector Manufacturing for Gene Therapy Market Share by Type (2019-2030)
9.3 Asia Viral Vector Manufacturing for Gene Therapy Market Size by Application
9.3.1 Asia Viral Vector Manufacturing for Gene Therapy Market Size by Application (2019-2024)
9.3.2 Asia Viral Vector Manufacturing for Gene Therapy Market Size by Application (2025-2030)
9.3.3 Asia Viral Vector Manufacturing for Gene Therapy Market Share by Application (2019-2030)
9.4 Asia Viral Vector Manufacturing for Gene Therapy Market Size by Region
9.4.1 Asia Viral Vector Manufacturing for Gene Therapy Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Viral Vector Manufacturing for Gene Therapy Market Size by Region (2019-2024)
9.4.3 Asia Viral Vector Manufacturing for Gene Therapy Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Viral Vector Manufacturing for Gene Therapy Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Viral Vector Manufacturing for Gene Therapy Market Size by Type
10.2.1 Middle East, Africa, and Latin America Viral Vector Manufacturing for Gene Therapy Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Viral Vector Manufacturing for Gene Therapy Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Viral Vector Manufacturing for Gene Therapy Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Viral Vector Manufacturing for Gene Therapy Market Size by Application
10.3.1 Middle East, Africa, and Latin America Viral Vector Manufacturing for Gene Therapy Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Viral Vector Manufacturing for Gene Therapy Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Viral Vector Manufacturing for Gene Therapy Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Viral Vector Manufacturing for Gene Therapy Market Size by Country
10.4.1 Middle East, Africa, and Latin America Viral Vector Manufacturing for Gene Therapy Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Viral Vector Manufacturing for Gene Therapy Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Viral Vector Manufacturing for Gene Therapy Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Thermo Fisher Scientific
11.1.1 Thermo Fisher Scientific Company Details
11.1.2 Thermo Fisher Scientific Business Overview
11.1.3 Thermo Fisher Scientific Viral Vector Manufacturing for Gene Therapy Introduction
11.1.4 Thermo Fisher Scientific Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.1.5 Thermo Fisher Scientific Recent Development
11.2 Lonza
11.2.1 Lonza Company Details
11.2.2 Lonza Business Overview
11.2.3 Lonza Viral Vector Manufacturing for Gene Therapy Introduction
11.2.4 Lonza Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.2.5 Lonza Recent Development
11.3 Catalent
11.3.1 Catalent Company Details
11.3.2 Catalent Business Overview
11.3.3 Catalent Viral Vector Manufacturing for Gene Therapy Introduction
11.3.4 Catalent Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.3.5 Catalent Recent Development
11.4 Charles River
11.4.1 Charles River Company Details
11.4.2 Charles River Business Overview
11.4.3 Charles River Viral Vector Manufacturing for Gene Therapy Introduction
11.4.4 Charles River Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.4.5 Charles River Recent Development
11.5 Merck
11.5.1 Merck Company Details
11.5.2 Merck Business Overview
11.5.3 Merck Viral Vector Manufacturing for Gene Therapy Introduction
11.5.4 Merck Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.5.5 Merck Recent Development
11.6 SK pharmteco
11.6.1 SK pharmteco Company Details
11.6.2 SK pharmteco Business Overview
11.6.3 SK pharmteco Viral Vector Manufacturing for Gene Therapy Introduction
11.6.4 SK pharmteco Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.6.5 SK pharmteco Recent Development
11.7 Oxford Biomedica
11.7.1 Oxford Biomedica Company Details
11.7.2 Oxford Biomedica Business Overview
11.7.3 Oxford Biomedica Viral Vector Manufacturing for Gene Therapy Introduction
11.7.4 Oxford Biomedica Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.7.5 Oxford Biomedica Recent Development
11.8 AGC Biologics（MolMed）
11.8.1 AGC Biologics（MolMed） Company Details
11.8.2 AGC Biologics（MolMed） Business Overview
11.8.3 AGC Biologics（MolMed） Viral Vector Manufacturing for Gene Therapy Introduction
11.8.4 AGC Biologics（MolMed） Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.8.5 AGC Biologics（MolMed） Recent Development
11.9 Gene Universal
11.9.1 Gene Universal Company Details
11.9.2 Gene Universal Business Overview
11.9.3 Gene Universal Viral Vector Manufacturing for Gene Therapy Introduction
11.9.4 Gene Universal Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.9.5 Gene Universal Recent Development
11.10 Polyplus (Sartorius)
11.10.1 Polyplus (Sartorius) Company Details
11.10.2 Polyplus (Sartorius) Business Overview
11.10.3 Polyplus (Sartorius) Viral Vector Manufacturing for Gene Therapy Introduction
11.10.4 Polyplus (Sartorius) Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.10.5 Polyplus (Sartorius) Recent Development
11.11 CCRM
11.11.1 CCRM Company Details
11.11.2 CCRM Business Overview
11.11.3 CCRM Viral Vector Manufacturing for Gene Therapy Introduction
11.11.4 CCRM Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.11.5 CCRM Recent Development
11.12 FUJIFILM Diosynth Biotechnologies
11.12.1 FUJIFILM Diosynth Biotechnologies Company Details
11.12.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.12.3 FUJIFILM Diosynth Biotechnologies Viral Vector Manufacturing for Gene Therapy Introduction
11.12.4 FUJIFILM Diosynth Biotechnologies Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.12.5 FUJIFILM Diosynth Biotechnologies Recent Development
11.13 Biovian
11.13.1 Biovian Company Details
11.13.2 Biovian Business Overview
11.13.3 Biovian Viral Vector Manufacturing for Gene Therapy Introduction
11.13.4 Biovian Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.13.5 Biovian Recent Development
11.14 Miltenyi Bioindustry
11.14.1 Miltenyi Bioindustry Company Details
11.14.2 Miltenyi Bioindustry Business Overview
11.14.3 Miltenyi Bioindustry Viral Vector Manufacturing for Gene Therapy Introduction
11.14.4 Miltenyi Bioindustry Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.14.5 Miltenyi Bioindustry Recent Development
11.15 Aldevron
11.15.1 Aldevron Company Details
11.15.2 Aldevron Business Overview
11.15.3 Aldevron Viral Vector Manufacturing for Gene Therapy Introduction
11.15.4 Aldevron Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.15.5 Aldevron Recent Development
11.16 Takara Bio
11.16.1 Takara Bio Company Details
11.16.2 Takara Bio Business Overview
11.16.3 Takara Bio Viral Vector Manufacturing for Gene Therapy Introduction
11.16.4 Takara Bio Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.16.5 Takara Bio Recent Development
11.17 Yposkesi
11.17.1 Yposkesi Company Details
11.17.2 Yposkesi Business Overview
11.17.3 Yposkesi Viral Vector Manufacturing for Gene Therapy Introduction
11.17.4 Yposkesi Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.17.5 Yposkesi Recent Development
11.18 Genezen
11.18.1 Genezen Company Details
11.18.2 Genezen Business Overview
11.18.3 Genezen Viral Vector Manufacturing for Gene Therapy Introduction
11.18.4 Genezen Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.18.5 Genezen Recent Development
11.19 Exthera
11.19.1 Exthera Company Details
11.19.2 Exthera Business Overview
11.19.3 Exthera Viral Vector Manufacturing for Gene Therapy Introduction
11.19.4 Exthera Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.19.5 Exthera Recent Development
11.20 Flash Therapeutics
11.20.1 Flash Therapeutics Company Details
11.20.2 Flash Therapeutics Business Overview
11.20.3 Flash Therapeutics Viral Vector Manufacturing for Gene Therapy Introduction
11.20.4 Flash Therapeutics Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.20.5 Flash Therapeutics Recent Development
11.21 VIVEBiotech
11.21.1 VIVEBiotech Company Details
11.21.2 VIVEBiotech Business Overview
11.21.3 VIVEBiotech Viral Vector Manufacturing for Gene Therapy Introduction
11.21.4 VIVEBiotech Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.21.5 VIVEBiotech Recent Development
11.22 FinVector
11.22.1 FinVector Company Details
11.22.2 FinVector Business Overview
11.22.3 FinVector Viral Vector Manufacturing for Gene Therapy Introduction
11.22.4 FinVector Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.22.5 FinVector Recent Development
11.23 Eurogentec
11.23.1 Eurogentec Company Details
11.23.2 Eurogentec Business Overview
11.23.3 Eurogentec Viral Vector Manufacturing for Gene Therapy Introduction
11.23.4 Eurogentec Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.23.5 Eurogentec Recent Development
11.24 VGXI
11.24.1 VGXI Company Details
11.24.2 VGXI Business Overview
11.24.3 VGXI Viral Vector Manufacturing for Gene Therapy Introduction
11.24.4 VGXI Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.24.5 VGXI Recent Development
11.25 GenScript ProBio
11.25.1 GenScript ProBio Company Details
11.25.2 GenScript ProBio Business Overview
11.25.3 GenScript ProBio Viral Vector Manufacturing for Gene Therapy Introduction
11.25.4 GenScript ProBio Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.25.5 GenScript ProBio Recent Development
11.26 EurekaBio
11.26.1 EurekaBio Company Details
11.26.2 EurekaBio Business Overview
11.26.3 EurekaBio Viral Vector Manufacturing for Gene Therapy Introduction
11.26.4 EurekaBio Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.26.5 EurekaBio Recent Development
11.27 Obio Technology
11.27.1 Obio Technology Company Details
11.27.2 Obio Technology Business Overview
11.27.3 Obio Technology Viral Vector Manufacturing for Gene Therapy Introduction
11.27.4 Obio Technology Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.27.5 Obio Technology Recent Development
11.28 GeneSail Biotech
11.28.1 GeneSail Biotech Company Details
11.28.2 GeneSail Biotech Business Overview
11.28.3 GeneSail Biotech Viral Vector Manufacturing for Gene Therapy Introduction
11.28.4 GeneSail Biotech Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.28.5 GeneSail Biotech Recent Development
11.29 VectorBuilder
11.29.1 VectorBuilder Company Details
11.29.2 VectorBuilder Business Overview
11.29.3 VectorBuilder Viral Vector Manufacturing for Gene Therapy Introduction
11.29.4 VectorBuilder Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.29.5 VectorBuilder Recent Development
11.30 WuXi ATU
11.30.1 WuXi ATU Company Details
11.30.2 WuXi ATU Business Overview
11.30.3 WuXi ATU Viral Vector Manufacturing for Gene Therapy Introduction
11.30.4 WuXi ATU Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.30.5 WuXi ATU Recent Development
11.31 Ubrigene
11.31.1 Ubrigene Company Details
11.31.2 Ubrigene Business Overview
11.31.3 Ubrigene Viral Vector Manufacturing for Gene Therapy Introduction
11.31.4 Ubrigene Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.31.5 Ubrigene Recent Development
11.32 Porton Biologics
11.32.1 Porton Biologics Company Details
11.32.2 Porton Biologics Business Overview
11.32.3 Porton Biologics Viral Vector Manufacturing for Gene Therapy Introduction
11.32.4 Porton Biologics Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.32.5 Porton Biologics Recent Development
11.33 Pharmaron
11.33.1 Pharmaron Company Details
11.33.2 Pharmaron Business Overview
11.33.3 Pharmaron Viral Vector Manufacturing for Gene Therapy Introduction
11.33.4 Pharmaron Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.33.5 Pharmaron Recent Development
11.34 PackGene Biotechnology
11.34.1 PackGene Biotechnology Company Details
11.34.2 PackGene Biotechnology Business Overview
11.34.3 PackGene Biotechnology Viral Vector Manufacturing for Gene Therapy Introduction
11.34.4 PackGene Biotechnology Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.34.5 PackGene Biotechnology Recent Development
11.35 Hillgene
11.35.1 Hillgene Company Details
11.35.2 Hillgene Business Overview
11.35.3 Hillgene Viral Vector Manufacturing for Gene Therapy Introduction
11.35.4 Hillgene Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.35.5 Hillgene Recent Development
11.36 Asymchem
11.36.1 Asymchem Company Details
11.36.2 Asymchem Business Overview
11.36.3 Asymchem Viral Vector Manufacturing for Gene Therapy Introduction
11.36.4 Asymchem Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024)
11.36.5 Asymchem Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
- 13.1.1.1 Research Programs/Design
- 13.1.1.2 Market Size Estimation
- 13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
- 13.1.2.1 Secondary Sources
- 13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer